Developing innovative treatments that meet physicians’ and patients’ needs

Dermavant is developing the treatments dermatologists want and for which their patients have been waiting. The company’s medical dermatology pipeline includes commercialized, late-stage, and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Chart illustrating development stages of Dermavant product candidates, including: Tapinrof, cerdulatinib, Oxybutynin, and DMV-503.

Chart illustrating development stages of Dermavant product candidates, including: Tapinrof, cerdulatinib, Oxybutynin, and DMV-503.